Tony Vernon Joins Medivation's Board of Directors

Medivation, Inc. (AMEX:MDV) today announced that Tony
Vernon joined its board of directors on July 14, 2006. Mr. Vernon has
23 years experience serving in senior executive positions at various
Johnson & Johnson companies, including as Company Group Chairman of
DePuy Orthopedics, Inc., President of Centocor, Inc., President of
McNeil Consumer Healthcare, and President Worldwide of the Johnson &
Johnson/Merck Joint Venture.
   David Hung, MD, President and Chief Executive Officer of
Medivation, stated: "We are delighted to welcome Tony Vernon to our
board of directors. Tony's substantial executive management experience
at Johnson & Johnson spans pharmaceuticals, biologics and medical
devices, and includes corporate partnerships with multiple life
sciences companies such as Lilly, Schering, Merck, Tanabe and
Yamanouchi. The background and experience that Tony brings to
Medivation are a perfect fit with our business model and growth
strategy, and a superb complement to the skill sets already
represented on our board."
   The appointment of Mr. Vernon increases Medivation's board
membership to five directors, three of whom are independent. Mr.
Vernon also will join Medivation's other two independent directors on
the board's audit, compensation, and nominating and corporate
governance committees.

   About Medivation

   Medivation, Inc. acquires promising pharmaceutical and medical
device technologies in the late preclinical development phase, and
develops those technologies quickly and cost-effectively through human
first proof-of-efficacy studies (generally the end of Phase 2 clinical
trials). Depending on the indication, Medivation will either seek to
sell or partner successful programs with larger pharmaceutical,
biotechnology and medical device companies for late-stage clinical
studies and commercialization, or alternatively conduct those
activities internally. The Company intends to build and maintain a
portfolio of 4 to 6 development programs at all times.
   Medivation's current portfolio consists of small molecule drugs in
development to treat 3 large, unmet medical needs -- Alzheimer's
disease, Huntington's disease and hormone-refractory prostate cancer,
the last two of which are likely Orphan Drug indications. Dimebon(TM),
with a 20-year record of human use and demonstrated efficacy in animal
studies of both Alzheimer's disease (AD) and Huntington's disease (HD)
and in a pilot clinical study of AD, is in a randomized, double-blind,
placebo-controlled Phase 2 study in AD patients in Russia, the results
of which are expected to be available this quarter. Medivation also
expects to initiate a Phase 1-2a study of Dimebon in HD patients in
2006. The MDV300 series compounds are in development for the treatment
of hormone-refractory prostate cancer, and are expected to enter
clinical studies in the first half of 2007. Further information about
Medivation can be found on its website (www.medivation.com).

   Safe Harbor Statement

   This press release contains forward-looking statements, including
statements regarding the anticipated timing of regulatory and clinical
milestones on the Company's Alzheimer's disease, Huntington's disease
and hormone-refractory prostate cancer programs, which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve
risks and uncertainties that could cause actual results to differ
significantly from those projected. You are cautioned not to place
undue reliance on the forward-looking statements, which speak only as
of the date of this release. Our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-KSB for
the year ended December 31, 2005 and our Quarterly Report on Form
10-QSB for the quarter ended March 31, 2006, include more information
about factors that could affect our financial and operating results.